Markets
BP

The Zacks Analyst Blog Highlights: Facebook, Celgene, BlackRock, Danaher and BP

For Immediate Release

Chicago, IL - November 7, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Facebook FB , Celgene CELG , BlackRock BLK , Danaher DHR and BP BP .

Here are highlights from Monday's Analyst Blog:

Top Stock Reports for Facebook, Celgene and BlackRock

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Facebook, Celgene and BlackRock. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today's research reports here >>>

Facebook 's shares have outperformed the S&P 500 index over the last year, gaining +46.5% vs. +21.3%. Facebook reported strong third quarter 2017 results as mobile and live video efforts continue to pay off in a big way. Instagram remains another important revenue stream.

Apart from mobile and video, the monetization opportunities of the company's other subsidiaries - Messenger, WhatsApp and Oculus - and a huge user base/higher engagement levels are expected to drive growth going ahead. Facebook is also dabbling in AR/VR and AI technologies, which bodes well for long term growth.

However, due to the recent uproar caused by apparent usage of the platform by Russian elements for interfering in the election process has put Facebook in a spot. As a result, Facebook CEO Mark Zuckerberg has said that it will make sizable investments to tighten security on the platform which along with continued investments in video, AR/VR and AI, will dent operating margins going ahead.

(You can read the full research report on Facebook here >>> ) .

Shares of Celgene have underperformed the Zacks Biomedical and Genetics industry in the year so far, losing -13.6% vs. an increase of +3.9%. Celgene's third-quarter results were mixed with the company beating on earnings but missed on sales estimates.

While Revlimid sales were impressive yet again, Otezla sales in the United States were weak due to challenges in the dermatology market which led the management to cut guidance. Celgene's Revlimid continued to outperform driven by further market share increases in newly diagnosed myeloma and the continued increase in treatment duration. Pomalyst and Abraxane also performed well.

The Zacks analyst likes the company's progress with its label expansion efforts and pipeline development. The approval of Idhifa in the United States for relapsed and/or refractory acute myeloid leukemia has further boosted the company's portfolio.

However, Celgene is highly dependent on Revlimid while Abraxane sales are under competitive pressure. Weakness in Otezla's performance will also remain a headwind.

(You can read the full research report on Celgene here >>> ) .

Buy-rated BlackRock 's shares have outperformed the Zacks Investment Management industry in the last six months, (+25.3% vs. +16.9%). This performance is supported by impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in three of the trailing four quarters.

The company's third quarter 2017 earnings were supported by a rise in revenues and steady asset inflows while higher expenses were the undermining factor. The Zacks analyst likes Blackrock's initiatives to restructure its actively managed equities business with an aim to meet changing client needs.

These efforts, along with technological changes and its attempt to expand globally via acquisitions will further help top-line growth going forward. However, mounting expenses mainly due to continued rise in marketing costs and high dependence on overseas revenues remain major concerns.

(You can read the full research report on BlackRock here >>> ) .

Other noteworthy reports we are featuring today Danaher and BP.

Wall Street's Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.

Click for details >>

Want more stock market analysis from this author? Make sure to follow @ Ryan_McQueeney on Twitter!

Wall Street's Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius. Click for details >>

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Facebook, Inc. (FB): Free Stock Analysis Report

Danaher Corporation (DHR): Free Stock Analysis Report

BlackRock, Inc. (BLK): Free Stock Analysis Report

Celgene Corporation (CELG): Free Stock Analysis Report

BP p.l.c. (BP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BP DHR FB BLK CELG

Other Topics

Stocks